NBIA Disorders Association (NBIADA) and Hoffnungsbaum e.V. (HoBa)
Research Grant Call Invitation Information
for
Pantothenate Kinase-associated Neurodegeneration (PKAN)
Submission Deadline for Letter of Interest (LOI) February 28, 2026
Submission Deadline for Requested Applications is May 30, 2026
Research Objectives
NBIADA and HoBa, together “The Funders,” are currently accepting applications from invited participants for a one or two-year grant proposal not to exceed $100,000 USD for research studies related to the treatment of individuals with PKAN.
Our research objectives for the PKAN 2026 Collaborative Grant Call are to support high-quality, translational research that advances meaningful therapeutic progress for individuals living with PKAN. The Funders seek to support new or ongoing meritorious projects that advance the development or evaluation of therapeutic approaches for PKAN, including small molecules, gene-based therapies, biologics, repurposed drugs, or combination approaches, with a clear path toward clinical relevance.
Proposed studies may address key barriers to translation, such as delivery, safety, dosing, manufacturing readiness, or the generation of proof-of-concept data, and should demonstrate a rationale for how the work may improve symptoms, slow disease progression, or alter the course of PKAN. Prospective applicants must first submit a brief Letter of Interest, which will be used to assess programmatic relevance, alignment with the objectives of the call, and appropriateness for full application. Selected applicants will then be invited to submit a full proposal.
Projects may be preclinical or early translational in nature and will be evaluated using NIH-style peer review criteria. Final funding decisions will be made by the Funders.
